Garrett Wong, MD
Cardiovascular Disease · Sacramento, CANPI 1336112085
Payments from drug & device makers
Across 1,217 payments — averaging $414.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$135K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$83K
- Teleflex LLC$50K
- Chiesi USA, Inc.$49K
- Boston Scientific$45K
- Philips North America LLC$36K
- plus $107K from 31 others
What the payments were for
- Consulting fees$85,66817%
- Speaking & faculty fees$283,99756%
- Travel & lodging$73,40415%
- Food & beverage$61,16912%
- Education$1380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 150 | $135,281 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 144 | $83,073 |
| Teleflex LLC | 66 | $50,186 |
| Chiesi USA, Inc. | 59 | $49,192 |
| Boston Scientific | 168 | $44,820 |
| Philips North America LLC | 137 | $35,711 |
| Abbott | 94 | $29,434 |
| Asahi Intecc USA, Inc. | 48 | $19,785 |
| Edwards Lifesciences | 108 | $17,359 |
| Biotronik Inc. | 46 | $13,647 |
| Medtronic(2 entities) | 37 | $4,453 |
| Cordis US CORP. | 10 | $4,383 |
| Abiomed | 61 | $3,690 |
| Arrow International, Inc. | 1 | $2,925 |
| Amgen | 14 | $2,555 |
| Penumbra, Inc. | 7 | $2,445 |
| Corindus Inc. | 6 | $1,720 |
| Recor Medical Inc | 9 | $877 |
| W. L. Gore & Associates, Inc. | 12 | $649 |
| Reflow Medical Inc | 5 | $522 |
| Janssen Research & Development, LLC | 1 | $402 |
| Cardiovascular Systems Inc. | 3 | $336 |
| Cvrx, Inc. | 2 | $263 |
| Acist Medical Systems, Inc. | 2 | $152 |
| Cathworks, Inc. | 5 | $145 |
| Novartis | 1 | $138 |
| Angiodynamics, Inc. | 2 | $119 |
| Kestra Medical Technology Services, Inc. | 1 | $117 |
| AstraZeneca | 4 | $58 |
| Livanova USA, Inc. | 1 | $57 |
| Pfizer | 2 | $51 |
| Irhythm Technologies, Inc. | 2 | $48 |
| EKOS Corporation | 2 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Bardy Diagnostics, Inc. | 1 | $39 |
| Terumo Medical Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$128,541
- LifeVest$80,275
- KENGREAL$48,224
- GUIDELINER$25,731
- GUIDELINER V3 CATHETER$20,761
- CROSSBOSS$20,358
- (9520) IGT Devices Undivided$19,949
- ASAHI PTCA Guide Wire$17,634
- Xience V coronary stent system$16,205
- Edwards SAPIEN 3 Transcatheter Heart Valve$13,515
- GENERAL VASCULAR ACCESS$11,952
- XIENCE SIERRA$6,887
- Vascular Lithotripsy$4,637
- TURNPIKE$4,276
- (6574) Coronary Other$3,781
- Indigo$3,548
- COREVALVE EVOLUT R$2,871
- GENERAL - THERAPIES$2,433
- Repatha$2,314
- DRAGONFLY OPSTAR$2,237
How this compares
$504,777 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 97 | $138,434 |
| BrilintaTicagrelor | 84 | $83,481 |
| Repatha SureclickEvolocumab | 23 | $24,999 |
| JardianceEmpagliflozin | 13 | $15,163 |
| Praluent PenAlirocumab | 24 | $11,885 |
| Metoprolol Succinate | 283 | $5,177 |
| Atorvastatin Calcium | 241 | $3,241 |
| Rosuvastatin Calcium | 184 | $3,150 |
| Nitroglycerin | 82 | $1,865 |
| Lisinopril | 137 | $1,623 |
| ClopidogrelClopidogrel Bisulfate | 130 | $1,507 |
| Amlodipine Besylate | 220 | $1,506 |
| Metoprolol Tartrate | 114 | $1,386 |
| Prasugrel Hcl | 24 | $1,368 |
| Valsartan | 35 | $1,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $51 | $138,43497 claims |
| AstraZenecaBrilinta | $58 | $83,48184 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Sacramento
- Jason RogersSacramento$5.1M
- Gagan SinghSacramento$2M
- Jeffrey SouthardSacramento$1.8M
- Thomas SmithSacramento$942K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.